MedKoo Biosciences:UNBS5162

Back to products

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

Other drug agents

Drug intermediates

Bio-reagents and biochemicals

MedKoo product information:

UNBS5162

MedKoo Code#: 203071

Name: UNBS5162

CAS#: 956590-23-1

Synonym: UNBS-5162; UNBS 5162; UNBS5162. Urea, N-[2-[2-(dimethylamino)ethyl]-2,3-dihydro-1,3-dioxo-1H-benz[de]isoquinolin-5-yl]-.

IUPAC/Chemical name:

1-(2-(2-(dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea

Chemical structure:

Theoretical analysis

Chemical Formula: C17H18N4O3

Exact Mass: 326.13789

Molecular Weight: 326.34982

m/z: 326.13789 (100.0%), 327.14125 (18.4%), 328.14460 (1.6%), 327.13493 (1.5%)

Elemental Analysis: C, 62.57; H, 5.56; N, 17.17; O, 14.71

Availability and price:

This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

Quality control data:

Product will be shipped with supporting analytical data.

Information about this agent

Full genome array analyses involving revealed that UNBS5162 is a cytostatic compound that appears to interfere in vivo with amino acid metabolism in hormone-refractory prostate cancer cells.
Amino acid metabolism perturbations relate to ERS and UPR. UNBS5162 displays anti-tumor activity in orthotopic human xenografts of prostate cancer and NSCLC models, and in subcutaneous models of human breast cancer xenografts. Ongoing in vivo experiments aim to demonstrate that UNBS5162 sensitizes various types of cancers to the cytotoxic effects of pro-apoptotic drugs and to radiotherapy

According to Unibioscreen 's website, The UNBS5162 IND has been cleared by the FDA early July 2008. The Phase I trial is currently being conducted under the supervision of Daniel Von Hoff, M.D. at TGen Clinical Research Services at The Virginia G. Piper Cancer Center at Scottsdale Healthcare, Mayo Clinic Scottsdale and the University of Arizona Cancer Center Tucson.
On August 22, 2008, Unibioscreen and Drais Pharmaceuticals have entered into a global agreement to develop and commercialize UNBS5162.

Current developer: Unibioscreen SA, 40 Avenue Joseph Wybran, 1070 Brussels, Belgium.

References

1. Mijatovic T, Mahieu T, Bruyère C, De Nève N, Dewelle J, Simon G, Dehoux MJ, van der Aar E, Haibe-Kains B, Bontempi G, Decaestecker C, Van Quaquebeke E, Darro F, Kiss R.UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia, 2008 Jun;10(6):573-86.

2. Van Quaquebeke, Eric; Simon, Gentiane; El Yazidi, Mohamed; Tuti, Jerome; Van den Hove, Laurent; Darro, Francis; Kiss, Robert. (Unibioscreen S.A., Belg.). Compositions and methods for treatment of prostate and breast cancer using novel ureyl-substituted naphthalimide derivs. U.S. Pat. Appl. Publ. (2009), 56pp., Cont.-in-part of U.S. Ser. No. 227,090. CODEN: USXXCO US 2009221628 A1 20090903 Patent written in English. Application: US 2008-313186 20081117. Priority: US 2006-746560 20060505; GB 2006-8900 20060505; WO 2007-EP3991 20070507; US 2008-227090 20081105. CAN 151:328863 AN 2009:1080988 CAPLUS

Contact MedKoo:

Email: sales@medkoo.com

(Keyword; CAS#; MedKoo code#)